Louisiana sub­scribes to Gilead­'s Net­flix-style plan for hep C; Ono is in­vest­ing mil­lions in a new I/O re­search al­liance

→ Re­mem­ber the con­tro­ver­sy over Gilead’s big price for a hep C cure? That’s all over. In a sign of the new times, the state Louisiana is sign­ing up for a Net­flix sub­scrip­tion mod­el to cov­er the state’s poor and prison pop­u­la­tion. They’re pay­ing a flat fee to Asegua Ther­a­peu­tics, a sub­sidiary of Gilead, to gain ac­cess to as much of the triple com­bo they need to treat some of the state’s most vul­ner­a­ble res­i­dents.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER